Literature DB >> 35532821

Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.

Yuqing Song1, Yuelun Zhang2, Zhuo Li1, Jing Liu1, Juan Xiao3, Hongmei Song4.   

Abstract

Immune thrombocytopenia (ITP) patients are at risk developing to systemic lupus erythematosus (SLE) in the future. Our study attempted to explore the potential risk factors for the development from ITP to SLE in Chinese children by statistical analysis. This study was a retrospective case-control study. Patients diagnosed with ITP and developed to SLE after the diagnosis of ITP were defined as the case group. The control group consisted of children with ITP but without developing to SLE was recruited with a ratio of 1:2. Besides univariable analysis, multivariable logistic regression was built to evaluate the potential risk factors. A total of 150 children was included with 50 in the case group and 100 in the control group. Median developing time from ITP to SLE was 34.5 [IQR 12.5, 58.75] months. ANA was found significantly different between the two groups in our study in the univariable analysis but not in the multivariable analysis (OR = 4.50, 95% CI 0.97 to 21.01). Age diagnosed ITP was positively associated with SLE (OR = 1.07 every 5 years, 95% CI 1.01 to 1.15) with alert point at 8 years old (sensitivity 0.82, specificity 0.60). A lower level of complement was also positively associated with SLE (OR = 8.33, 95% CI 1.62 to 42.91). A minimum 3-year of close follow-up for pediatric ITP patients was recommended to monitor the risk for developing SLE. Older age and hypocomplementemia were potential risk factors for the development from ITP to SLE.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antinuclear antibody; Children; Complement; Immune thrombocytopenia; Systemic lupus erythematosus

Mesh:

Year:  2022        PMID: 35532821     DOI: 10.1007/s00277-022-04836-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  30 in total

1.  Significance of a positive antinuclear antibody test in a pediatric population.

Authors:  D S Chudwin; A J Ammann; M J Cowan; D W Wara
Journal:  Am J Dis Child       Date:  1983-11

Review 2.  Pathogenesis of immune thrombocytopenia.

Authors:  Douglas B Cines; Adam Cuker; John W Semple
Journal:  Presse Med       Date:  2014-03-12       Impact factor: 1.228

3.  Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura.

Authors:  Rawi Hazzan; Mashaand Mukamel; Joanne Yacobovich; Isaac Yaniv; Hannah Tamary
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

Review 4.  A clinical overview of systemic lupus erythematosus in childhood.

Authors:  B A Lang; E D Silverman
Journal:  Pediatr Rev       Date:  1993-05

5.  Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database.

Authors:  Mellissa Yong; Wilma Marieke Schoonen; Lin Li; Gena Kanas; Jenna Coalson; Fionna Mowat; Jon Fryzek; James A Kaye
Journal:  Br J Haematol       Date:  2010-04-04       Impact factor: 6.998

6.  The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease.

Authors:  P M Deane; G Liard; D M Siegel; J Baum
Journal:  Pediatrics       Date:  1995-06       Impact factor: 7.124

Review 7.  Autoimmunity and novel therapies in immune-mediated thrombocytopenia.

Authors:  Dana Yehudai; Elias Toubi; Yehuda Shoenfeld; Zahava Vadasz
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

8.  A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura.

Authors:  Salah Yousef Abbasi; Mohammed Milhem; Luna Zaru
Journal:  Ann Hematol       Date:  2008-02-12       Impact factor: 3.673

Review 9.  Contemporary concepts for the clinical and laboratory evaluation of systemic lupus erythematosus and "lupus-like" syndromes.

Authors:  R M Nakamura; D J Bylund
Journal:  J Clin Lab Anal       Date:  1994       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.